How does health technology assessment (HTA), the process behind reimbursing medical services and medicines, work overseas? How does it meet the needs and perspectives of patients and their communities?
Watch us chat with our international peers Kate Morgan (Myeloma Patients Europe), Zack Pemberton-Whitely (Leukaemia Care, UK) and Deb Maskens (Kidney Cancer Canada and International Kidney Cancer Coalition) about how and when they’re involved in HTA, pathways to earlier access, what works well and what changes they want to see in their own system.
